Biology Reference
In-Depth Information
multiple matrix (tissue, blood, and urine) metab-
olomic analysis. The HPLC/MS and GC/MS
analysis resulted in the identi
of bladder cancer.
Expert Opin Biol Ther
2010;
10
:
1169
e
80.
5. Glas AS, Roos D, Deutekom M, et al. Tumor markers in
the diagnosis of primary bladder cancer: A systematic
review.
J Urol
2003;
cation of 267
metabolites in tissue, 246 in serum, and 267 in
urine, of which 89 were common to the three
matrices. The results also indicated that serum
analysis is a more accurate proxy for tissue
changes than urine.
When all of the above-mentioned factors are
resolved, we
:1975
e
82.
6. Villicana P, Whiting B, Goodison S, Rosser CJ. Urine-
based assays for the detection of bladder cancer.
Bio-
mark Med
2009;
169
:265.
7. National Cancer Institute, NCI.
Prostate-Speci
3
c Antigen
(PSA) Test
,
http://www.cancer.gov/cancertopics/
factsheet/Detection/PSA
; 2009.
8. Thompson IM, Ankerst DP, Chi CA, et al. Operating
characteristics of prostate-speci
firmly believe that continued
research will
c
biomarkers for various cancers. It is only a matter
of time and effort. Although a single discovered
biomarker may not have 100% sensitivity and
speci
lead to sensitive and speci
c antigen in men with
an initial PSA level of 3.0 ng/ml or lower.
J Am Med
Assoc
2005;
:66
e
70.
9. Ebeling FG, Stieber P, Untch M, et al. Serum CEA and
CA 15-3 as prognostic factors in primary breast cancer.
Br J Cancer
2002;
294
city, it is possible that a combination of
biomarkers will minimize the number of false
positives and false negatives in population
screening. We believe that with further advance-
ments in MS, separation technologies, NMR
(speci
:1217
e
22.
10. van Nagell Jr JR, DePriest PD, Reedy MB, et al. The
ef
86
cacy of
transvaginal
sonographic
screening in
asymptomatic women at
risk for ovarian cancer.
:350
e
6.
11. Niloff JM, Knapp RC, Schaetzl E, et al. CA125 antigen
levels in obstetric and gynecologic patients.
Obstet
Gynecol
1984;
Gynecol Oncol
2000;
77
cally for metabolomics), and the use of
reproducible and accurate analytical procedures,
more clinically useful biomarkers will be
discovered.
:703
e
7.
12. Horstmann M, Patschan O, Hennenlotter J, et al.
Combinations of urine-based tumor markers in bladder
cancer surveillance.
Scand J Urol Nephrol
2009;
64
43
:461
e
6.
13. PubMed search, April 2012.
14. Hsieh SY, Chen RK, Pan YH, et al. Systematical eval-
uation of the effects of sample collection procedures
on low-molecular-weight
Acknowledgments
This project has been funded in whole or in part with federal
funds from the National Cancer Institute, National Institutes
of Health, under Contract HHSN261200800001E. The content
of this publication does not necessarily re
serum/plasma proteome
:3189
e
98.
15. Tammen H, Schulte I, Hess R, et al. Peptidomic analysis
of human blood specimens: comparison between
plasma specimens and serum by differential peptide
display.
Proteomics
2005;
pro
ling.
Proteomics
2006;
6
ect the views or
policies of the Department of Health and Human Services,
nor does mention of trade names, commercial products, or
organizations imply endorsement by the United States
Government.
:3414
e
22.
16. Liu LAJ, Wang G, et al. Differences in metabolite pro
5
le
between blood plasma and serum.
Anal Biochem
2010;
406
:105
e
12.
17.
Issaq HJ, Xiao Z, Veenstra TD. Serum and plasma
proteomics.
Chem Rev
2007;
:3601
e
20.
18. Lawton KA, Berger A, Mitchell M, et al. Analysis of the
adult human plasma metabolome.
Pharmacogenomics
2008;
107
References
1. Bocket C, Coleman M, Collins B, et al. Photoaptamer
arrays applied to multiplexed proteomic analysis.
Pro-
teomics
2004;
:383
e
97.
19. West-Nielsen M, Hogdall EV, Marchiori E, et al. Sample
handling for mass spectrometric proteomic investiga-
tions of human sera.
Anal Chem
2005;
9
:609
e
18.
2. MacNeil JS. Better biomarkers for the diagnostics
labyrinth.
Genome Technol
2004;24
e
33.
3. Apolo AB, Milowsky M, Bajorin DF. Clinical states
model for biomarkers in bladder cancer.
Future Oncol
2009;
4
:5114
e
23.
20. Baumann S, Ceglarek U, Fiedler GM, et al. Standard-
ized approach to proteome pro
77
ling of human serum
based on magnetic bead separation and matrix-assisted
laser desorption/ionization time-of-
:977
e
92.
4. Lintula S, Hotakainen K. Developing biomarkers for
improved diagnosis and treatment outcome monitoring
5
ight mass spec-
trometry.
Clin Chem
2005;
51
:973
e
80.
Search WWH ::
Custom Search